What’s stopping cell and gene therapy from using AI to learn from its own mistakes – and what will it take to finally start sharing our failures?

In this opinion piece for BioSpace, our CEO Alexander Seyf argues that CGT is still in its “pre-black box” era, much like aviation before a string of tragedies forced airlines to start sharing safety data instead of guarding it. He makes the case that when one gene therapy program hits a safety setback, it resets the risk conversation for the entire field – yet the industry still treats scientific, manufacturing, and post-treatment data as separate silos.

“We are still trying to use flat-head screwdrivers on star-shaped screws,” says Seyf, on why CGT keeps borrowing tools built for traditional pharma instead of redesigning workflows for a digital-first field.

He also lays out why AI’s real value lies in connecting the dots between data sets, not the math itself, and why shared failures, not just shared successes, are what the industry needs most.

Read the full piece – including why Alexander believes the industry’s “zero-sum game mentality” around IP is the biggest obstacle to progress – here.